会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF TRANSPORTER 1 AND GLYCINE TRANSPORTER 2
    • 作为运输车辆1和糖果运输车辆2的抑制剂的DIAZA-螺旋磷酸二氢吡啶衍生物
    • WO2005068462A1
    • 2005-07-28
    • PCT/EP2004/014840
    • 2004-12-30
    • F. HOFFMANN-LA ROCHE AGJOLIDON, SynesePINARD, EmmanuelTHOMAS, Andrew, William
    • JOLIDON, SynesePINARD, EmmanuelTHOMAS, Andrew, William
    • C07D471/10
    • C07D471/10
    • The present invention relates to compounds of formula (I) wherein A-B is CH 2 -CH 2 , -CH 2 -O-, O-CH 2 , CH 2 -S, -S-CH 2 -, CH 2 -C(O)-, C(O)-CH 2 -, .-N(R 4 )-CH 2 - or -CH 2 -N(R 4 )-; R 1 is lower alkyl, lower alkenyl, cycloalkyl, or is aryl, optionally substituted by one or two substituents, selected from the group consisting of halogen, cyano, lower alkyl, CF 3 , OCF 3 or lower alkoxy, or is heteroaryl, optionally substituted by one or two substituents selected from the group consisting of halogen, lower alkyl, CF 3 or lower alkoxy; R 2 is lower alkyl, cycloalkyl, or is aryl, optionally substituted by one or two substituents, selected from the group consisting of halogen, lower alkyl, CF 3 , lower alkoxy, or is heteroaryl, optionally substituted by one or two substituents, selected from the group consisting of halogen, lower alkyl, CF 3 , lower alkoxy, or is heteroaryl, optionally substituted by one or two substituents, selected from the group consisting of halogen, lower alkyl, CF 3, or lower alkoxy; R 3 is hydrogen, lower alkyl or benzyl; R 4 is hydrogen or benzyl; n is 0, 1 or 2; and to pharmaceutically available salts thereof. The compounds of formula I may be used in the treatment of neurological and neuropsychiatric disorders.
    • 本发明涉及式(I)化合物,其中AB是CH 2 -CH 2,-CH 2 -O-,O-CH 2,CH 2 -S,-S-CH 2 - ,CH 2 -C(O) - ,C(O) -CH 2 - , - N(R 4)-CH 2 - 或-CH 2 -N(R 4) - ; R 1是低级烷基,低级烯基,环烷基或芳基,任选地被一个或两个选自卤素,氰基,低级烷基,CF 3,OCF 3或低级烷氧基的取代基取代,或者是杂芳基,任选地 被一个或两个选自卤素,低级烷基,CF 3或低级烷氧基的取代基取代; R 2是低级烷基,环烷基或芳基,任选被一个或两个选自卤素,低级烷基,CF 3,低级烷氧基或被一个或两个取代基取代的杂芳基取代的取代基取代, 选自卤素,低级烷基,CF 3,低级烷氧基或杂芳基,任选被一个或两个选自卤素,低级烷基,CF 3或低级烷氧基的取代基取代; R 3是氢,低级烷基或苄基; R 4是氢或苄基; n为0,1或2; 及其药学上可用的盐。 式I化合物可用于治疗神经和神经精神障碍。
    • 6. 发明申请
    • 4- (SULFANYL-PYRIMIDIN-4-YLMETHYL) -MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY
    • 4-(SULFANYL-吡啶基-4-甲基乙基) - 吗啉衍生物及相关化合物作为GABA受体配体,用于治疗放射性疾病,恶化和恶化
    • WO2005094828A1
    • 2005-10-13
    • PCT/EP2005/001814
    • 2005-02-22
    • F. HOFFMANN-LA ROCHE AGMALHERBE, PariMASCIADRI, RaffaelloPRINSSEN, EricSPOOREN, WillTHOMAS, Andrew, William
    • MALHERBE, PariMASCIADRI, RaffaelloPRINSSEN, EricSPOOREN, WillTHOMAS, Andrew, William
    • A61K31/506
    • C07D239/38C07D239/42C07D401/06C07D403/06C07D413/06C07D471/14C07D491/10
    • The present invention relates to compounds of Formula (I) wherein X is -S- or -NH-; R 1 is alkyl, alkenyl, arylalkyl, arylalkenyl or aryl-O-alkyl, wherein the aryl groups are optionally substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or lower halogen-alkyl; R 2 is hydrogen, lower alkyl or cycloalkyl; R 3 /R 4 may form together with the N-atom to which they are attached a non aromatic5, 6 or 7 membered ring, which may contain in addition to the N-atom one additional heteroatom selected from the group consisting of O, S or N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, -NR 2 , -CONR 2 , -CO-lower alkyl or benzyl; or may form together with the N-atom to which they are attached a heterocyclic ring system, containing at least two rings and which may contain one or two additional heretoatoms, selected from the group consisting of N or O; R is hydrogen or lower alkyl; R 5 is hydrogen or lower alkyl; and to pharmaceutically suitable acid addition salts thereof. It has been found that the compounds are active on the GABA B receptor and therefore useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders or gastro-intestinal disorders.
    • 本发明涉及其中X为-S-或-NH-的式(I)化合物; R 1是烷基,烯基,芳基烷基,芳基烯基或芳基-O-烷基,其中芳基任选被一个或多个选自下列的取代基取代:低级烷基,低级烷氧基,卤素或低级卤代烷基 ; R 2是氢,低级烷基或环烷基; R 3 / R 4可以与它们所连接的N-原子一起形成非芳族5,6或7元环,除了N-原子外,还可以含有一个另外的杂原子,该杂原子选自 的O,S或N,并且其中所述环任选被羟基,低级烷基,低级烷氧基,-NR 2,-CONR 2,-CO-低级烷基或苄基取代; 或者可以与它们所连接的N-原子一起形成含有至少两个环的杂环体系,并且可以含有一个或两个选自N或O的另外的原子, R是氢或低级烷基; R 5是氢或低级烷基; 和其药学上合适的酸加成盐。 已经发现这些化合物对GABA B受体有活性,因此可用于治疗焦虑,抑郁,癫痫,精神分裂症,认知障碍,痉挛和骨骼肌僵硬,脊髓损伤,多发性硬化,肌萎缩性侧索硬化,脑性麻痹 ,神经性疼痛和与可卡因和尼古丁相关的渴望,精神病,恐慌症,创伤后应激障碍或胃肠疾病。
    • 10. 发明申请
    • TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS
    • 作为GABA受体调节剂的四氢咪唑并苯并嗪
    • WO2006063708A1
    • 2006-06-22
    • PCT/EP2005/012993
    • 2005-12-05
    • F.HOFFMANN-LA ROCHE AGBUETTELMANN, BerndKNUST, HennerTHOMAS, Andrew, William
    • BUETTELMANN, BerndKNUST, HennerTHOMAS, Andrew, William
    • C07D487/14A61K31/5517
    • C07D487/14
    • The present invention is concerned with substituted imidazo [1,5-a] [1,2,4] triazolo [1,5-d] [1,4]benzodiazepine derivatives of the following formula (I) wherein R' is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, nitro, cycloalkyl, -O(CH 2 ) m O(CH 2 ) m OH or -C≡C-R'; R 2 is hydrogen or methyl; R 3 is lower alkyl, lower alkyl substituted by halogen, lower alkenyl, lower alkenyl substituted by halogen, lower alkynyl, -(CH 2 ) n -cycloalkyl, -(CR'R") m CH 3 , or is phenyl, unsubstituted or substituted by halogen, or is pyridinyl or thienyl, unsubstituted or substituted by lower alkyl, or is -(CH 2 ) n -NH-cycloalkyl, lower alkenyl-cycloalkyl, lower alkynyl-(CR'R") m OH, or is lower alkynyl-phenyl, wherein the phenyl ring is unsubstituited or substituted by halogen, CF 3 , lower alkyl or lower alkoxy; R' is hydrogen or lower alkyl; R" is hydrogen, hydroxy or lower alkyl; n is 0, 1 or 2; m is 1, 2 or 3; o is 1 or 2; and with their pharmaceutically acceptable acid addition salts. It has been found that this class of compounds show high affinity and selectivity for GABA A α 5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
    • 本发明涉及下式(I)的取代咪唑并[1,5-a] [1,2,4]三唑并[1,5-d] [1,4]苯并二氮杂衍生物,其中R'是氢, 卤素,低级烷基,被卤素取代的低级烷基,低级烷氧基,被卤素取代的低级烷氧基,硝基,环烷基,-O(CH 2) OH或-C = C-R'; R 2是氢或甲基; R 3是低级烷基,被卤素取代的低级烷基,低级烯基,被卤素取代的低级链烯基,低级炔基, - (CH 2 SO 2)n